BIOMÉRIEUX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.15 EUR | +2.91% |
|
+1.57% | -3.43% |
| May. 29 | BioMérieux: head injury test cleared by the FDA | CF |
| May. 28 | BioMérieux: FDA clearance for Vidas TBI test | CF |
| Sales 2024 * | 3.9B 4.23B | Sales 2025 * | 4.19B 4.55B | Capitalization | 11.48B 12.45B |
|---|---|---|---|---|---|
| Net income 2024 * | 468M 508M | Net income 2025 * | 529M 574M | EV / Sales 2024 * | 2.88 x |
| Net cash position 2024 * | 264M 287M | Net cash position 2025 * | 447M 485M | EV / Sales 2025 * | 2.63 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
22.2
x | Employees | 13,696 |
| Yield 2024 * |
0.89% | Yield 2025 * |
1.03% | Free-Float | 36.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
| 1 day | +2.91% | ||
| 1 week | +2.59% | ||
| Current month | -2.85% | ||
| 1 month | -2.85% | ||
| 3 months | -5.31% | ||
| 6 months | -1.63% | ||
| Current year | -3.43% |
1 week
92.65
97.15
1 month
91.80100.90
Current year
91.80108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 14 M€ | -5.07% | ||
| 0.26% | 1,083 M€ | +4.80% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 97.15 | +2.91% | 690,760 |
| 24-05-30 | 94.4 | +0.69% | 95,625 |
| 24-05-29 | 93.75 | -0.42% | 96,516 |
| 24-05-28 | 94.15 | -1.00% | 82,308 |
| 24-05-27 | 95.1 | -0.58% | 86,737 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-06-06
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
97.15
EUR
Average target price
114.2
EUR
Spread / Average Target
+17.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.43% | 12.1B | |
| -3.17% | 8.24B | |
| +31.98% | 5.58B | |
| -10.03% | 4.15B | |
| -59.94% | 2.68B | |
| +11.23% | 2.63B | |
| -5.14% | 2.24B | |
| +18.91% | 2.03B | |
| -7.56% | 1.79B | |
| +3.07% | 1.56B |
- Stock Market
- Equities
- BIM Stock
